All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2017-02-01T17:59:05.000Z

The impact of tetraploidy/near-tetraploidy karyotype in AML

Feb 1, 2017
Share:

Bookmark this article

Tetraploidy or Near Tetraploidy (T/NT), a complex karyotype with numerical or structural abnormality, is a rare cytogenetic abnormality in Acute Myeloid Leukemia (AML). AML patients with T/NT karyotype are usually grouped in the high-risk cytogenetic AML category. The clinical significance and prognostic impact of T/NT karyotype in AML is unclear, thus the rationale for this study.

Lanshan Huang from the University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, and colleagues published data from their study in Leukemia Research. The article was originally published ahead of print on 2nd December 2016.

In this study, the authors analyzed the cytogenetics, pathology, and survival outcomes of 38 AML patients (median age = 65 years; men = 26 and women = 12) with T/NT karyotype from the MDACC database between the years of 2000 to 2015.  

The key results are:

  • The Bone Marrow (BM) of patients (n = 38) with T/NT karyotype had large blasts with prominent nucleoli (n = 30)
  • Large blast features included cytoplasmic vacuoles (n = 16), cytoplasmic inclusions (n = 14), irregular contours (n = 14), and nuclear budding (n = 8)
  • 29% (n = 11) of patients had T/NT karyotype with <3 additional chromosomal abnormalities (non-complex), 71% (n = 27) of patients had T/NT karyotype with ≥3 additional chromosome abnormalities (complex), and 55% (n = 21) of patients had pseudodiploid/triploid clones
  • After detection of T/NT karyotype, patients were treated with chemotherapy (n = 32) and allogenic Stem Cell Transplantation (allo-SCT) (n = 10)
  • At median follow-up of 6.2 months, 12% (n = 5) of patients were alive in Complete Remission (CR), 32 patients died from SCT associated complications, and 1 patient had persistent AML
  • Median Overall Survival (OS) in male and female patients were 7.8 and 3.5 months respectively; P = 0.021
  • Median OS in patients with complex T/NT karyotype (n = 27) was significantly worse than patients with non-complex T/NT karyotype (n = 11); 3.4 and 10.7 months respectively; P = 0.0287
  • Complex T/NT karyotype was associated with poor prognosis; HR = 2.879, P = 0.0037

In summary, T/NT karyotype is characterized by distinctive morphological features and it is associated with poor outcomes in AML patients. Additionally, patients with non-complex T/NT karyotype convey an intermediate risk and they have a better prognosis compared to patients with complex T/NT karyotype.

The author concluded by suggesting that complex T/NT karyotype should be distinguished from non-complex T/NT karyotype in order to provide more prognostic information for AML patients.  

Abstract

A tetraploid/near tetraploid (T/NT) karyotype is a rare finding in acute myeloid leukemia (AML). Here we report 38 AML patients with a T/NT karyotype, including 26 men and 12 women with a median age of 65 years. T/NT karyotype was detected at initial diagnosis of AML in 16 patients, and acquired during the course of disease in 22 patients. All patients showed large blasts with frequent prominent nucleoli, cytoplasmic vacuoles and/or inclusions, nuclear irregularity and/or budding. Eleven patients had a non-complex and 27 had a complex T/NT karyotype; 21 patients also had pseudodiploid and/or triploid clones. After T/NT karyotype detection, 32 patients received chemotherapy and 10 also received stem cell transplant. After a median of 6.2 months follow-up, 32 patients died of disease or complications, 5 were alive with complete remission, and 1 alive with persistent AML. Median overall survival (OS) was 5 months. Patients with a non-complex T/NT karyotype had a significantly superior OS compared to those with a complex T/NT karyotype (10.7 vs. 3.4 months, p=0.0280). We conclude that T/NT karyotype in AML is often associated with distinctive morphologic features and conveys generally poor outcomes. Distinction of complex versus non-complex T/NT karyotype provides further prognostic information.

  1. Huang L.et al. Tetraploidy/near-tetraploidy acute myeloid leukemia. Leukemia Research. 2017 Feb; 53(2017): 20–27. DOI: 10.1016/j.leukres.2016.11.016. Epub 2016 Dec 2.
More about...

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
29 votes - 47 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox